" Reliq Health Technologies (TSXV:RHT) commences clinical trials and announces new contracts
Reliq Health Technologies (RHT) announced that its iUGO Care platform will go live in two clinical trials this month involving over 1,000 patients.
" Defence Therapeutics (CSE:DTC) reports that AccuVAC-PTE7 vaccine provides protection from cervical cancer
Defence Therapeutics (DTC) has announced the development of a dual-acting Accum-linked protein vaccine, AccuVAC-PTE7.
" ScreenPro Security (CSE:SCRN) provides update on Concierge medical business operations
ScreenPro’s (SCRN) wholly-owned operating subsidiary Concierge Medical Consultants is growing its client base to help provide personalized healthcare to Canadians.
" Sienna Senior Living (TSX:SIA) acquires ownership interest in 11 properties in Ontario and Saskatchewan
Sienna (SIA) has acquired a 50 per cent ownership interest in a portfolio of 11 seniors’ living assets in Ontario and Saskatchewan.
" Sernova (TSXV:SVA) enters partnership to develop and commercialize infinite insulin therapy
Sernova (SVA) has announced a partnership with Evotec SE to develop a cell therapy treatment for diabetic insulin users.
" Extendicare (TSX:EXE.TO) completes sale of Esprit Retirement Communities
Extendicare (EXE.TO) has completed the sale of its retirement living operations located in Ontario and Saskatchewan to Sienna-Sabra LP for $307.5 million.
" StageZero (TSX:SZLS) expands its cancer diagnostic aid programs
StageZero Life Sciences, Ltd. (SZLS) has launched its COC Plus Program for patients currently in the COC Protocol/TREAT Program.
" Viemed (TSX:VMD.TO) patient claims receive large coverage from Medicare
Viemed Healthcare (VMD.TO) has been approved for claim funds by the U.S. Department of Health and Human Services Office of Inspector General (OIG).
" Aeterna Zentaris (TSX:AEZS) updates results from pre-clinical studies of its AIM Biologicals platform
Aeterna Zentaris (AEZS) has updated results from pre-clinical studies of its AIM Biologicals platform to treat Parkinson’s disease.
" NervGen Pharma (TSXV:NGEN) receives approval to proceed to the final dose cohort in clinical trial of NVG-291
NervGen Pharma Corp. (NGEN) has received approval to advance to the final dose cohort in the Phase 1 Clinical Trial of NVG-291.